On this pageKey Takeaways
Short answer: PTT-A is an investigational, long-acting peptide from Pep2Tango Therapeutics designed as a quadruple receptor agonist (a tetra-agonist): one molecule built to activate the GLP-1, GIP, amylin and calcitonin receptors. Its developer describes it as joining the incretin activity of a GLP-1/GIP dual agonist and the amylin/calcitonin activity of an agonist like cagrilintide in a single peptide. The research published so far is preclinical: cell assays and rodent studies presented as conference abstracts.
This page covers what PTT-A is, how each of its four receptor targets fits in, how it differs from retatrutide, what the published abstracts report, and why identity testing matters for multi-agonist peptides.
Key Takeaways
- Four targets, one molecule. PTT-A is designed to activate GLP-1R, GIPR, amylin receptors and the calcitonin receptor (CTR).
- Developer: Pep2Tango Therapeutics, a company launched by Versant Ventures in November 2024 and led by Cristina Rondinone, Ph.D.
- Not a retatrutide variant. Retatrutide targets GLP-1, GIP and glucagon receptors. PTT-A swaps glucagon for amylin and calcitonin receptor activity.
- Preclinical stage. Published findings are American Diabetes Association conference abstracts (2024 and 2025) in cells and rodents. As of October 2026 we found no published human results.
- Identity is not public. No sequence, CAS number or molecular formula has been publicly tied to the PTT-A designation in the sources we reviewed.
What Is PTT-A?
PTT-A is an experimental synthetic peptide classified as a tetra-agonist: a single molecule designed to activate four receptor systems. Its reported targets are:
- Glucagon-like peptide-1 receptor (GLP-1R)
- Glucose-dependent insulinotropic polypeptide receptor (GIPR)
- Amylin receptors
- Calcitonin receptor (CTR)
Pep2Tango Therapeutics presented its first PTT-A findings at the American Diabetes Association’s Scientific Sessions in 2024, with further data at EASD 2024 and ADA 2025. Coverage of the EASD 2024 data describes a half-life similar to tirzepatide’s.
PTT-A extends the multi-receptor approach behind dual agonists such as tirzepatide and triple agonists such as retatrutide. For background on that class, see what is a triple agonist.
How Does PTT-A Work?
PTT-A combines four receptor activities in one molecule. All four are class B G protein-coupled receptors, and laboratories usually measure their activation in cell assays that read out cyclic AMP (cAMP).
1. GLP-1 receptor
GLP-1 receptors take part in glucose-dependent insulin secretion and gastrointestinal signaling. They are the shared core of almost every incretin multi-agonist.
2. GIP receptor
GIP receptors also take part in glucose-dependent insulin signaling. Research on combined GLP-1 and GIP activation led to dual agonists like tirzepatide.
3. Amylin receptors
Amylin is a peptide hormone released alongside insulin by pancreatic beta cells. Amylin receptor signaling is studied for its role in gastric emptying and food-intake signaling. Amylin analogs such as cagrilintide and eloralintide are studied on their own and in combinations.
4. Calcitonin receptor
The calcitonin receptor takes part in calcium regulation. It also forms the core of amylin receptors: when the calcitonin receptor pairs with a receptor activity-modifying protein (RAMP1, 2 or 3), the complex responds to amylin.
Scientific distinction: because amylin receptors are built on the calcitonin receptor, PTT-A’s four targets are not four fully independent pathways. Its amylin and calcitonin activities overlap at the receptor level, the same pairing seen in dual amylin and calcitonin receptor agonists (DACRAs) like cagrilintide.
PTT-A vs Retatrutide: What’s the Difference?
Both are multi-receptor agonists, but their receptor profiles differ.
| Receptor target | PTT-A | Retatrutide |
|---|---|---|
| GLP-1 | Yes | Yes |
| GIP | Yes | Yes |
| Glucagon | Not a reported target | Yes |
| Amylin | Yes | Not a reported target |
| Calcitonin | Yes | Not a reported target |
| Class | Quadruple (tetra-) agonist | Triple agonist |
| Developer | Pep2Tango Therapeutics | Eli Lilly and Company |
| Stage | Preclinical (published data) | Phase 3 (TRIUMPH program) |
PTT-A is not retatrutide with a fourth target added. It is a different molecule built on a different strategy, and the two are not chemically equivalent or interchangeable. For a comparison of two triple agonists, see UBT251 vs retatrutide.
What Has Research Found About PTT-A?
The published PTT-A data are conference abstracts in the journal Diabetes. They are summarized here as research context only. They are animal findings, have not appeared as full peer-reviewed papers, and come from the developer’s own researchers.
2024: Discovery and receptor characterization
The ADA 2024 abstract (299-OR) described long-acting tetra-agonists, including PTT-A. In cAMP assays the compound showed agonism at all four target receptors. In acute studies in lean rodents it lowered blood glucose (an incretin effect) and blood calcium (an amylin/calcitonin effect) and reduced food intake. In longer studies in diet-induced obese (DIO) rats, the authors reported lower cumulative food intake and body weight, driven by fat-mass reduction without the loss of muscle mass seen with tirzepatide.
2025: Three-week comparison with tirzepatide
The ADA 2025 abstract (85-OR; Ghosh, Valdecantos, Rada, Valverde and Rondinone) compared PTT-A with tirzepatide in DIO rats over three weeks. Researchers reported body-weight reductions versus vehicle of about 14% and 19% at two tested levels of PTT-A, mostly from fat, against about 12.1% with tirzepatide. Tirzepatide reduced gastrocnemius and soleus muscle weights by about 26%; PTT-A at the same level did not reduce muscle weight. Body composition was measured by carcass analysis and MRI.
These results are specific to the animal model and study conditions. They do not show what would happen in humans, and no head-to-head human comparison exists.
Why PTT-A’s Molecular Structure Matters
Small changes to a peptide’s amino acid sequence or chemical modifications can change its receptor binding, signaling potency, stability, half-life and selectivity across receptors. They also change how it is identified analytically.
Pep2Tango has not publicly tied a specific sequence, CAS number or molecular formula to the PTT-A designation in the sources we reviewed. Patent filings on multi-agonist peptides can list many sequences, and a patent sequence shouldn’t be presented as PTT-A without a verified link to the research compound. Any material sold under the PTT-A name should be viewed with caution until a reference structure is public.
Analytical Testing for Multi-Agonist Peptides
The more complex a multi-agonist peptide, the more its characterization matters. Laboratories look at separate attributes:
- Identity: whether the sample’s structure matches the claimed compound, typically by mass spectrometry with orthogonal methods.
- Chromatographic purity: HPLC measures detectable impurities and related species. Purity alone does not prove identity.
- Peptide content: how much of the target peptide is present. Content and purity are different measurements.
- Stability: degradation and storage-related changes that affect molecular integrity.
See our guide to reading a peptide certificate of analysis.
Is PTT-A Being Studied in Humans?
When it launched in November 2024, Pep2Tango said it was running IND-enabling studies and expected to submit an IND in 2025. As of October 2026 we found no published human data for PTT-A, and the findings cited here are from cell assays and rodents. Human safety, pharmacokinetics and outcomes have not been established, and animal results can’t reliably predict human outcomes.
What PTT-A Means for Peptide Research
PTT-A reflects a broader move toward engineering several receptor activities into one peptide. Open research questions include:
- How does four-receptor activation shape intracellular signaling?
- Which balance of receptor potencies gives a particular pharmacological profile?
- How do structural modifications affect stability?
- How does a single tetra-agonist compare with a combination of separate agonists, such as a GLP-1/GIP agonist given alongside cagrilintide?
For the wider receptor landscape, see our metabolic peptide receptor research overview.
Conclusion
PTT-A combines GLP-1, GIP, amylin and calcitonin receptor agonism in one investigational molecule, a different strategy from dual and triple agonists. Early cell and rodent studies report receptor activity and body-composition findings, but PTT-A remains preclinical, its reference structure isn’t public, and its human relevance is unknown. For researchers it highlights how much receptor pharmacology, structural characterization and rigorous testing matter.
References
- Rondinone CM, et al. 299-OR: Discovery of Long-Acting Unimolecular Peptide Tetra-agonists Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors for Enhanced Metabolic Benefits in Animal Models of Obesity. Diabetes, 2024; 73 (Supplement 1). diabetesjournals.org
- Ghosh S, Valdecantos P, Rada P, Valverde AM, Rondinone CM. 85-OR: A Novel Unimolecular Peptide Tetra-agonist (PTT-A) Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors with Superior Weight Loss Effects vs. Tirzepatide While Preserving Muscle in DIO Rats. Diabetes, 2025; 74 (Supplement 1). diabetesjournals.org
- Pharmaceutical Technology. EASD 2024: Are tetra-agonists the future of metabolic diseases treatment? pharmaceutical-technology.com
- Fierce Biotech. Versant unveils Pep2Tango, a next-gen peptide biotech, November 2024. fiercebiotech.com
- Ongoing research: PubMed search and ClinicalTrials.gov search.
This article is for scientific and educational purposes. It summarizes published research on an investigational compound and is not guidance for human or veterinary use. References to third-party research do not imply affiliation, endorsement or product equivalence.